Evidence map›Paper›PMID 26582836›Full record

ArticleJournal of clinical microbiology2016

Multicenter Evaluation of MRSASelect II Chromogenic Agar for Identification of Methicillin-Resistant Staphylococcus aureus from Wound and Nasal Specimens.

Diana R Hernandez, Duane W Newton, Nathan A Ledeboer, Blake Buchan, Carol Young, Andrew E Clark, Jessica Connoly, Donna M Wolk

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Novel applications for a noninvasive sampling method of the nasal mucosa.American journal of physiology. Lung cellular and molecular physiology · 2017
    Article
  7. Methicillin-ResistantIndian journal of nephrology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Diana R HernandezGeisinger Health System, Danville, Pennsylvania, USA drhernandez@geisinger.edu.ORCID http://orcid.org/0000-0003-1377-4438
Duane W NewtonUniversity of Michigan Health System, Ann Arbor, Michigan, USA.
Nathan A LedeboerMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Blake BuchanMedical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID http://orcid.org/0000-0002-4111-048X
Carol YoungUniversity of Michigan Health System, Ann Arbor, Michigan, USA.
Andrew E ClarkUniversity of Arizona, Tucson, Arizona, USA.
Jessica ConnolyMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Donna M WolkGeisinger Health System, Danville, Pennsylvania, USA.
Medical College of Wisconsin · USGeisinger Health System · USMichigan Medicine · USUniversity of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hospitals strive to reduce methicillin-resistant Staphylococcus aureus (MRSA) prevalence via active surveillance of inpatient populations. Rapid and inexpensive screening methods are utilized when molecular methods are not operationally feasible. In this multisite clinical trial, the utility of Bio-Rad's MRSASelect II was evaluated for MRSA identification from remnant nares and wound swabs. The prevalence of MRSA was 11.1% (n = 1,384) from nares samples and 18.1% (n = 842) from wound samples. MRSASelect II had an overall concordance of 95.4% (confidence interval [CI] = 94.5% to 96.2%) compared to a broth-enriched reference standard. Comparisons between results, stratified by examination times, exhibited a nonsignificant trend toward increased positivity at prolonged incubation times. Cefoxitin screening of colonies directly from MRSASelect II was 96.7% (95.8% to 97.3%) concordant compared to testing of colonies following broth enrichment. A comparison of MRSASelect and MRSASelect II revealed no statistical differences; however, the latter exhibited earlier positivity, greater selectivity, and more intense indicator staining, which resulted in facilitated differentiation of positive results. MRSASelect II agar is a simple, rapid, and robust method to routinely screen patients for MRSA colonization without the need for additional testing.

Indexed as

Anti-Bacterial AgentsChromogenic CompoundsDisk Diffusion Antimicrobial TestsHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsNasal CavityPhenotypePrevalenceReproducibility of ResultsSensitivity and SpecificityStaphylococcal InfectionsWorkflowWounds and InjuriesAnti-Bacterial AgentsChromogenic Compounds

Identifiers

PMID26582836
PMCPMC4733205
OpenAlexW2178929404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.